CClinicalTrials.gg
Sign In
CompletedNCT00891345ALECSATUpdated Apr 27, 2012

Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

A Phase 1 interventional study of ALECSAT in Hormone-refractory Prostate Cancer, sponsored by CytoVac A/S. Completed at 1 site in Denmark. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-27.

Sponsored by CytoVac A/S · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This study is a phase I study of a new cell based prostate cancer therapy (ALECSAT). In this therapy specific cells from the patient's own immune system are isolated, activated and re-administered to the patient to boost a specific immune response against the cancer cells. The aim of the study is to show safety and tolerability for this type of therapy. It is the hypothesis that the cells administered during the therapy will attack the tumour cells and in this way stop or slow down the progression of disease.

Read the detailed description

This study is a prospective open phase I study to investigate the safety and tolerability of administration of a single dose of a cell based medicinal product (CBMP) ALECSAT.

ALECSAT is an autologous CBMP that is made from the patient's own blood cells. ALECSAT contains a large amount of tumour specific cytotoxic Lymphocytes (CTL) and Natural Killer (NK) cells that are isolated activated and amplified in number.

The CBMP is given as a slow i. v. injection to patients with prostate cancer. The patients are in the late stage of the disease where they have received hormone treatment but their disease is progressing.

The primary objective of the study is to observe if any side effects or tolerability issues occur as a consequence of the cell administration, secondarily it will be observed if any positive anti tumour effect may be observed. The study has the purpose to investigate whether treatment with ALECSAT in any way is toxic.

Trial Design: The study is an open, prospective phase I safety study of ALECSAT in prostate cancer patients.

A group consisting of 6 patients will be treated with ALECSAT according to the protocol. Then an interim analysis will be done. If there are no signs of significant toxicity related to the treatment, the study will continue with 8 more patients that will be included and treated with ALECSAT according to the phase I protocol. Thus this study will include a total of 14 patients.

The patients will after a single administration of ALECSAT be hospitalised for 3 days and will furthermore be followed closely for 7 weeks by 5 planned study visits, by the investigators at Urologisk Klinik at Fredrikssund Hospital.

02

Conditions studied

  • Hormone-refractory Prostate Cancer

Browse trials for

Keywords

  • hormone-refractory prostate cancer
  • Immunotherapy
03

In context

Prostatic Neoplasms

6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.

This study's enrollment of 13 is below the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

CytoVac A/S is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Hormone-refractory prostate cancer patients
  • Three consecutive rises of PSA min. 2 weeks apart, resulting in at least two 50% increases over the PSA nadir.
  • Antiandrogen withdrawal for at least 4 weeks, or
  • PSA progression despite secondary hormonal manipulations, or
  • Progression of osseous or soft tissue lesions.
  • Serum castration levels of testosterone.
  • Be capable of understanding the information and giving informed consent.
  • Expected survival time (life expectancy) of over 4 months.
  • Adequate performance status (WHO / ECOG Performance status score 2 or less).

Exclusion criteria

Exclusion Criteria:

  • Patients with a low blood count (haemoglobin \< 6.0 mmol/l).
  • Patients with lymphocyte-numbers below 0.8.
  • Patients known to be HIV and/or hepatitis positive i.e. patients positive in tests for anti-HIV-1/2; HBsAg, anti-HBc and Anti-HCV.
  • Patients known to have syphilis i.e. being positive in a Treponema Pallidum test.
  • Patients with uncontrolled serious bacterial, viral, fungal or parasitic infection.
  • Patients must have no clinically significant autoimmune disorders or conditions of immune suppression.
  • Patients that have been treated with corticosteroids (steroid hormones) or bisphosphonates or have been in chemotherapy or radiation treatment one month prior to inclusion in the clinical trial.
  • Fertile patients.
  • Patients that have received blood transfusions within 48 hours prior to donation of blood for ALECSAT production.
  • Patients must not have been included in other clinical trials 6 weeks prior to inclusion in the trial or be enrolled in other clinical trials during the ALECSAT clinical trial.
  • Any medical condition that will render participation in the study risky or, according to the investigator in charge, will make the assessment of side-effects difficult.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Interventions

  • BiologicalALECSAT

    Autologous activated CTL and NK-cells injected as a single intravenous injection.

06

What researchers measure

Primary outcomes

  1. The primary endpoint is to show safety and tolerability for the administration of ALECSAT to enable further clinical development of the ALECSAT therapy.

    Time frame: Within 7 weeks

Secondary outcomes

  1. The secondary endpoint for this study is to establish if any indications of a positive therapeutic effect on the prostate cancer may be observed.

    Time frame: Within 7 weeks

07

Study locations

1 site
  • Urological Clinic, Frederikssunds Hospital
    Frederikssund, DK-3600, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00891345
Lead sponsor
CytoVac A/S
Responsible party
Sponsor
First posted
May 1, 2009
Start date
Apr 2009
Primary completion
Jul 2010
Completion
Jul 2010
Last update
Apr 27, 2012

Study contacts

Hans-Henrik Meyhoff, MD
principal investigator · Urologisk Klinik, Frederikssund Hospital, Frederikssundsvej 30, 3600 Frederikssund

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Prostatic Neoplasms→

Other studies from this sponsor

CytoVac A/S

Start the discussion